top of page
young-doctor-making-sure-little-girl-is-fine-after-vaccination.jpg

GlomCon's Clinical Trial Portal

A platform to help HOPE 
find OPPORTUNITY

Featured Clinical Trials

Atypical Hemolytic Uremic Syndrome

Study Sponsor: Novartis Pharmaceuticals

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS).

IC-MPGN

Study Sponsor: Novartis Pharmaceuticals

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT).

C3 Glomerulopathy

Study Sponsor: Novartis Pharmaceuticals

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G).

IgA Nephropathy

Study Sponsor: Novartis Pharmaceuticals

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN).

shutterstock_562454995.jpg

GlomCon's Corporate Supporters

We gratefully acknowledge the support and partnership of corporations dedicated to improving the lives of patients with glomerular diseases. 

​

The support from our corporate members and our strategic partners allows us to come up with bold ideas and helps us pursue our mission.

Travere Therapeutics Supporter
Novartis supporter
1200px-Vertex_logo.svg.png
image.png
Calliditas Logo.webp

Contact Us

Questions? Concerns? Reach out to GlomCon's Clinical Trials team at support@glomcon.org

bottom of page